YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology firm specializing in DNA methylation-based cancer detection and ophthalmologic innovations, has announced a significant strategic move by entering into a Memorandum of Understanding (MOU) to merge with EG BioMed. This proposed merger aims to enhance their combined capabilities in cancer diagnostics and drug development driven by AI.
Details of the Proposed Merger
The MOU marks a critical step in the formation of an integrated, data-driven oncology platform that focuses on early cancer detection, real-world clinical data generation, and AI-enabled drug discovery. However, it is important to note that this MOU is non-binding, and there are no assurances that the acquisition will meet expected timelines or conditions.
- The anticipated closure of the transaction is projected for 2026, pending regulatory approvals and definitive agreements.
- Potential integration benefits could include revenue growth and platform expansion, although many assumptions and risks could affect these outcomes.
Strategic Rationale for the Merger
As the biotechnology landscape evolves with precision medicine and AI, competitive advantages are increasingly tied to the integration of high-quality biological data with advanced analytics and clinical execution. YD Bio believes that merging with EG BioMed could expedite growth from a technology-centric model into a more comprehensive, platform-based biotech organization informed by clinically validated molecular data.
EG BioMed contributes a robust diagnostics platform based on DNA methylation and clinically certified laboratory infrastructure, propelling YD Bio’s efforts in both diagnostic commercialization and therapeutic innovation. The strategic alliance aims to:
- Unify diagnostics, therapeutics, and clinical data with AI intelligence.
- Mitigate development risks and accelerate time-to-market.
- Build an oncology-focused innovation ecosystem that addresses cancer from detection to treatment.
Synergies and Technological Advancements
EG BioMed’s technology is anchored in DNA methylation profiling, a potent method for detecting cancer-associated molecular changes. This platform has demonstrated efficacy in early detection, particularly for challenging cases like pancreatic cancer, known for its high mortality rate and unmet medical needs.
The merger allows YD Bio to convert DNA methylation data into valuable assets for AI-powered drug development, enhancing:
- AI-based target discovery.
- Patient stratification.
- Recurrence-risk prediction.
Comments from Leadership
“Prior to this announcement, EG BioMed’s cancer detection platform was approved for clinical use at three affiliated medical centers of Taipei Medical University. Its integration into hospital workflows will support clinicians in patient monitoring regarding treatment responses, disease progress, and recurrence,” said Dr. Ethan Shen, Chairman and CEO of YD Bio.
The Company anticipates that early clinical adoption may not only showcase the platform’s economic and clinical value but could also drive broader acceptance and diagnostics revenue growth across other institutions.
About YD Bio Limited
YD Bio Limited is committed to advancing clinical trials, drug development, and cancer diagnostics with the aim of transforming therapies for diseases with significant unmet medical needs. This includes innovations in limbal stem cell therapy and exosome therapies focused on improving patient outcomes through scientific advancements and precision medicine. YD Bio has also expanded into clinical trial drug supply and auxiliary product distribution.
For more information about YD Bio Limited and its initiatives, please visit ir.ydesgroup.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the MOU with EG BioMed, including potential synergies, expected timing, and the ability to finalize agreements. Such statements are based on current expectations and are not guarantees of future performance. Investors should be aware that actual results may differ due to various factors including regulatory decisions and market conditions, and are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission for further details.
Contact Information
For investor and media inquiries, please contact:
- YD Bio Limited
Email: investor@ydesgroup.com - WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214